Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1999 Nov 8;161(45):6169-73.

[Neoadjuvant chemotherapy in non-small-cell lung cancer]

[Article in Danish]
S S Larsen  1 , J J Pedersen, M Krasnik, T S Jensen
Affiliations
  • PMID: 10603752
Review

[Neoadjuvant chemotherapy in non-small-cell lung cancer]

[Article in Danish]
S S Larsen et al. Ugeskr Laeger. .

Abstract

Over the past 10 years, several studies of neoadjuvant chemotherapy for stage III Non Small Cell Lung Cancer (NSCLC) have been conducted. In eight Phase II studies, response rates of approximately 65% and resectability rates of approximately 50% have been achieved, with acceptable side effects. Two randomized trials with a total of 120 patients with stage IIIA cancer have been carried out to compare the effect of neoadjuvant chemotherapy plus surgery versus surgery alone. The trials were terminated early when interim analysis showed significantly increased survival in groups that received neoadjuvant chemotherapy. The incidences of treatment-related death did not differ significantly between the groups. Neoadjuvant chemotherapy for patients in stage III NSCLC is feasible and might prolong survival. However, the results of larger randomized trials must be awaited before firm general recommendations can be made.

PubMed Disclaimer

Similar articles

See all similar articles

MeSH terms

LinkOut - more resources